“…Our study revealed the findings of no statistically significant difference in the timeline or overall comparative BCR risk, when analyzed from our data on patient PSM being present or not. The framework for tissue regeneration with dHACM is, in part, contributed by tumor growth factor beta and interleukin-10, which may impact RARP patients favorably as seen in other pathological studies [ 20 ]. Recent work on cell cycle progression scores in prostate specimens [ 21 ] may challenge the prognostic value of PSM overall, among other parameters.…”